Management of systemic prostate cancer : current algorithm from castration sensitive to castration resistant setting
In recent years, the advanced knowledge of clinical, biological and molecular features of prostate cancer have led to the introduction of new drugs and have allowed the relocation of old drugs in different settings. In this way, the new concepts of systemic disease arise: high risk or high volume vs. low risk and low volume disease castration sensitive prostate cancer (CSPC), diversifying the use of previously approved drugs (CRPC) and opening new scenarios for sequence therapy. The aim of this review is to integrate new developments into the medical management of systemic prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
European review for medical and pharmacological sciences - 26(2022), 22 vom: 01. Nov., Seite 8481-8501 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
D'Aniello, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.12.2022 Date Revised 10.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.26355/eurrev_202211_30384 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349715890 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349715890 | ||
| 003 | DE-627 | ||
| 005 | 20231226043303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26355/eurrev_202211_30384 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349715890 | ||
| 035 | |a (NLM)36459030 | ||
| 035 | |a (PII)30384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a D'Aniello, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of systemic prostate cancer |b current algorithm from castration sensitive to castration resistant setting |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2022 | ||
| 500 | |a Date Revised 10.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In recent years, the advanced knowledge of clinical, biological and molecular features of prostate cancer have led to the introduction of new drugs and have allowed the relocation of old drugs in different settings. In this way, the new concepts of systemic disease arise: high risk or high volume vs. low risk and low volume disease castration sensitive prostate cancer (CSPC), diversifying the use of previously approved drugs (CRPC) and opening new scenarios for sequence therapy. The aim of this review is to integrate new developments into the medical management of systemic prostate cancer | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Cavaliere, C |e verfasserin |4 aut | |
| 700 | 1 | |a Foglia, C |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, S |e verfasserin |4 aut | |
| 700 | 1 | |a Uricchio, F |e verfasserin |4 aut | |
| 700 | 1 | |a Balsamo, R |e verfasserin |4 aut | |
| 700 | 1 | |a Franzese, E |e verfasserin |4 aut | |
| 700 | 1 | |a De Falco, S |e verfasserin |4 aut | |
| 700 | 1 | |a Izzo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Laterza, M |e verfasserin |4 aut | |
| 700 | 1 | |a Liguori, C |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, P |e verfasserin |4 aut | |
| 700 | 1 | |a Diessa, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, M |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lauro, G |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, S |e verfasserin |4 aut | |
| 700 | 1 | |a Cocetta, V |e verfasserin |4 aut | |
| 700 | 1 | |a Pisconti, S |e verfasserin |4 aut | |
| 700 | 1 | |a Montesarchio, V |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 26(2022), 22 vom: 01. Nov., Seite 8481-8501 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:22 |g day:01 |g month:11 |g pages:8481-8501 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202211_30384 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 22 |b 01 |c 11 |h 8481-8501 | ||